Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 14 for:    CC-122

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02509039
Recruitment Status : Active, not recruiting
First Posted : July 27, 2015
Last Update Posted : October 29, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

Tracking Information
First Submitted Date  ICMJE July 23, 2015
First Posted Date  ICMJE July 27, 2015
Last Update Posted Date October 29, 2019
Actual Study Start Date  ICMJE September 2, 2015
Actual Primary Completion Date March 30, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 23, 2015)
  • Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 2 weeks ]
    Number of participants with a DLT
  • Maximum Tolerated Dose (MTD) [ Time Frame: Up to 4weeks ]
    The last dose level with 0 or 1 out of 6 subjects experiencing Dose Limiting Toxicities (DLTs) during the DLT evaluation period.
  • Adverse Events (AEs) [ Time Frame: Apprximately 6 months ]
    Number of participants with adverse events
  • Pharmacokinetics -AUC [ Time Frame: Apprximately 2 weeks ]
    Area under the plasma concentration time-curve
  • Pharmacokinetics - Cmax [ Time Frame: Apprximately 2 weeks ]
    Peak (maximum) plasma concentration
  • Pharmacokinetics - t1/2 [ Time Frame: Apprximately 2 weeks ]
    Terminal half-life of (t1/2)
  • Pharmacokinetics - Tmax [ Time Frame: Apprximately 2 weeks ]
    Time to maximum plasma concentration (Tmax).
  • Pharmacokinetics - CL/F [ Time Frame: Apprximately 2 weeks ]
    Apparent clearance
  • Pharmacokinetics - Vz/F [ Time Frame: Apprximately 2 weeks ]
    Apparent volume of distribution
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02509039 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 23, 2015)
Antitumor activity [ Time Frame: Apprximately 6 months ]
Antitumor efficacy, determined by response rates in each tumor type using appropriate tumor response criteria, and duration of response
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Official Title  ICMJE A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Brief Summary To determine the safety and tolerability of CC-122 when administered orally to adult Japanese subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL) and to define the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Detailed Description

This is a phase 1, multicenter, open-label, dose-escalation study that will evaluate the safety, tolerability, (Pharmacokinetics) PK, and preliminary efficacy of CC-122 in Japanese subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL).

Subjects will receive ascending dose levels of CC-122 from Cycle 1 onwards to measure PK and to determine safety and tolerability.

An initial cohort of at least three subjects will be given CC-122 at a dose of 2.0 mg on an intermittent dosing schedule (5 continuous days out of 7 days per week) and 3-6 subjects will be enrolled in subsequent dose levels. Dose escalation for subsequent cohorts will proceed according to a standard dose escalation design (3+3 design) (Storer, 1989) to establish initial toxicity.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphoma, Non-Hodgkin
Intervention  ICMJE Drug: CC-122
5 continuous days out of 7 days per week intermittent dosing
Study Arms  ICMJE Experimental: CC-122
CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
Intervention: Drug: CC-122
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: April 15, 2016)
15
Original Estimated Enrollment  ICMJE
 (submitted: July 23, 2015)
12
Estimated Study Completion Date  ICMJE December 31, 2020
Actual Primary Completion Date March 30, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures are conducted
  2. 20 years or older, with histological or cytological confirmation of advanced solid tumors or Non-Hodgkin's Lymphoma (NHL), including those who have progressed on standard anticancer therapy or for whom no other conventional therapy exists
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 for all tumors
  4. Subjects must have the following laboratory values:

    ・Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

    • Hemoglobin (Hgb) ≥ 9 g/dL, drawn at least 7 days after the last RBC transfusion
    • Platelets (Plt) ≥ 100 x 109/L, drawn at least 7 days after the last platelet transfusion
    • Potassium within normal limits or correctable with supplements
    • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver tumors are present
    • Serum bilirubin ≤ 1.5 x ULN; subjects with serum bilirubin >1.5 x ULN and ≤ 2 x ULN may be enrolled if agreed to by the sponsor
    • Serum creatinine ≤ ULN or 24-hour clearance ≥ 50 mL/min
    • Negative serum pregnancy test in females of childbearing potential as per the CC-122 Pregnancy Prevention Rist Management Plan
  5. Able to adhere to the study visit schedule and other protocol requirements
  6. Must adhere to the Pregnancy Prevention Rist Management Plan

Exclusion Criteria:

  1. Subjects with primary central nervous system (CNS) malignancies or symptomatic central nervous system metastases. Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed
  2. Known acute or chronic pancreatitis
  3. Any peripheral neuropathy ≥ NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade 2
  4. Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management
  5. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    • Left Ventricular Ejection Fraction (LVEF) < 45% as determined by Multiple Gated Acquisition Scan (MUGA) scan or Echocardiogram (ECHO)
    • Complete left bundle branch, or bifascicular block

      • Congenital long QT syndrome
      • Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation
      • QTcF > 460 msec on screening electrocardiogram (ECG) (mean of triplicate recordings)
      • Unstable angina pectoris or myocardial infarction ≤ 3 months prior to starting CC-122
      • Troponin-T value >0.4 ng/mL or Brain Natriuretic Peptide (BNP) >300 pg/mL Subjects with baseline troponin-T >ULN or BNP >100 pg/mL are eligible but must and optimization of cardioprotective therapy.
    • Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mmHg)
  6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks, whichever is shorter, prior to starting CC-122 or who have not recovered from side effects of such therapy. Luteinizing hormone-releasing hormone (LHRH) agonists will be allowed for subjects with metastatic prostate cancer
  7. Major surgery ≤ 2 weeks prior to starting CC-122 or still recovering from post operative side effects
  8. Women who are pregnant or breast feeding. Adults of reproductive potential not employing two forms of birth control as per Pregnancy Prevention Risk Management Plan (PPRMP)
  9. Known human immunodeficiency virus (HIV) infection
  10. Known acute or chronic hepatitis B or C virus infection
  11. Status post solid organ transplant
  12. Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogeneic HSCT, or if otherwise not fully recovered from HSCT-related toxicity

    a. The 6-month exclusionary period for recovery from HSCT-associated toxicity, applies regardless of whether an autologous or allogeneic transplant was performed

  13. Known hypersensitivity to any component of the formulation of CC-122
  14. Any significant medical condition (including active or controlled infection or renal disease), laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  15. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  16. Any condition that confounds the ability to interpret data from the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02509039
Other Study ID Numbers  ICMJE CC-122-ST-002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Celgene
Study Sponsor  ICMJE Celgene
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Sasaki Toru Celgene
PRS Account Celgene
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP